Report an error   


HERDIN Record #: 100133-20070603244759 Submitted: 06 July 2020 Modified: 08 July 2020

Sorafenib resistance in hepatocellular carcinoma: The relevance of genetic heterogeneity.

Loraine Kay D. Cabral,
Claudio Tiribelli,
Caecilia H. Sukowati

See More

Despite advances in biomedicine, the incidence and the mortality of hepatocellular carcinoma (HCC) remain high. The majority of HCC cases are diagnosed in later stages leading to the less than optimal outcome of the treatments. Molecular targeted therapy with sorafenib, a dual-target inhibitor targeting the serine-threonine kinase Raf and the tyrosine kinases VEGFR/PDGFR, is at present the main treatment for advanced-stage HCC, either in a single or combinatory regimen. However, it was observed in a large number of patients that its effectiveness is hampered by drug resistance. HCC is highly heterogeneous, within the tumor and among individuals, and this influences disease progression, classification, prognosis, and naturally cellular susceptibility to drug resistance. This review aims to provide an insight on how HCC heterogeneity influences the different primary mechanisms of chemoresistance against sorafenib including reduced drug intake, enhanced drug efflux, intracellular drug metabolism, alteration of molecular targets, activation/inactivation of signaling pathways, changes in the DNA repair machinery, and negative balance between apoptosis and survival of the cancer cells. The diverse variants, mutations, and polymorphisms in molecules and their association with drug response can be a helpful tool in treatment decision making. Accordingly, the existence of heterogeneous biomarkers in the tumor must be considered to strengthen multi-target strategies in patient-tailored treatment.

Publication Type
Journal
Publication Sub Type
Journal Article, Original
Title
Cancers
Frequency
Others
Publication Date
June 2020
Volume
12
Issue
6
Page(s)
1576
LocationLocation CodeAvailable FormatAvailability
MDPI Website Abstract External Link (View)
MDPI Website Fulltext External Link (View)
Philippine Council for Health Research and Development Fulltext pdf (Request Document)
 

Copyright © One Window Project 2020. All rights reserved.